NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Forecast, Price & News

$10.15

-0.22 (-2.12%)

(As of 10/2/2023 ET)

Compare

Today's Range: $9.83
▼
$10.36
50-Day Range: $10.26
▼
$15.70
52-Week Range: $5.84
▼
$17.02

Volume: 469,662 shs
Average Volume: 395,157 shs
Market Capitalization: $576.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.33

Phathom Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 129.9% Upside
$23.33 Price Target
Short Interest: Bearish
10.76% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.79
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($4.07) to ($4.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

563rd out of 969 stocks

Pharmaceutical Preparations Industry

265th out of 452 stocks

3.5

Analyst's Opinion

Consensus Rating
Phathom Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.33, Phathom Pharmaceuticals has a forecasted upside of 129.9% from its current price of $10.15.
Amount of Analyst Coverage
Phathom Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
10.76% of the float of Phathom Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Phathom Pharmaceuticals has recently decreased by 0.36%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Phathom Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Phathom Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PHAT.

2.7

News and Social Media Coverage

News Sentiment
Phathom Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
4 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Phathom Pharmaceuticals is held by insiders.
Percentage Held by Institutions
93.14% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Phathom Pharmaceuticals are expected to decrease in the coming year, from ($4.07) to ($4.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Phathom Pharmaceuticals is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phathom Pharmaceuticals is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Phathom Pharmaceuticals (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT Price History

30 days | 90 days | 365 days | Advanced Chart

PHAT Stock News Headlines

September 30, 2023 | americanbankingnews.com

Needham & Company LLC Reiterates Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)

September 27, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Cardiff Oncology (CRDF) and Streamline Health Solutions (STRM)

October 2, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

September 26, 2023 | msn.com

Phathom files for FDA approval of vonoprazan for Non-Erosive GERD

September 26, 2023 | markets.businessinsider.com

Phathom Pharma Submits NDA To FDA For Vonoprazan To Treat Non-Erosive GERD

September 26, 2023 | finance.yahoo.com

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

September 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and TRACON Pharmaceuticals (TCON)

August 30, 2023 | msn.com

Phathom Pharmaceuticals (PHAT) Price Target Increased by 18.15% to 22.29

October 2, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

August 25, 2023 | prnewswire.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

August 24, 2023 | finance.yahoo.com

Reflux Testing Products Global Market Report 2023

August 22, 2023 | seekingalpha.com

Phathom submits additional data to FDA for esophagitis candidate

August 22, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP) and Phathom Pharmaceuticals (PHAT)

August 21, 2023 | finance.yahoo.com

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

August 18, 2023 | markets.businessinsider.com

JonesTrading downgrades Impel Pharmaceuticals (IMPL) to a Hold

August 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Phathom Pharmaceuticals (PHAT) Buy Recommendation

August 10, 2023 | markets.businessinsider.com

Goldman Sachs Reaffirms Their Hold Rating on Phathom Pharmaceuticals (PHAT)

August 10, 2023 | msn.com

Phathom Pharmaceuticals GAAP EPS of -$0.84 beats by $0.14

August 10, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Buy Recommendation

August 10, 2023 | finance.yahoo.com

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

August 7, 2023 | markets.businessinsider.com

JonesTrading Keeps Their Buy Rating on Ovid Therapeutics (OVID)

August 4, 2023 | markets.businessinsider.com

JonesTrading Remains a Buy on Longboard Pharmaceuticals (LBPH)

July 23, 2023 | fool.com

Phathom Pharmaceuticals (NASDAQ: PHAT)

July 14, 2023 | seekingalpha.com

Phathom Pharma: Time To Take Profits (Rating Downgrade)

July 7, 2023 | finance.yahoo.com

3 Top Breakout Stocks Worth a Buy for Attractive Returns

July 7, 2023 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Phathom Pharmaceuticals Stock

June 26, 2023 | markets.businessinsider.com

Stoke Therapeutics (STOK) Gets a Buy from Needham

See More Headlines

Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAT Company Calendar

Last Earnings: 8/10/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PHAT
CUSIP: N/A
CIK: 1783183
Web: www.phathompharma.com
Phone: 877-742-8466
Fax: N/A
Employees: 112
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $23.33
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +127.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-197,720,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -95.34%

Debt

Debt-to-Equity Ratio: 5.56
Current Ratio: 11.96
Quick Ratio: 11.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.80) per share
Price / Book: -5.71

Miscellaneous

Outstanding Shares: 56,800,000
Free Float: 52,543,000
Market Cap: $583.90 million
Optionable: Not Optionable
Beta: 0.56

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Ms. Terrie J. Curran (Age 54)
Pres, CEO & Director
Comp: $1.11M

Mr. David A. Socks (Age 48)
Co-Founder & Director
Comp: $58.78k

Dr. Azmi Nabulsi M.D. (Age 63)
M.P.H., Co-Founder & COO
Comp: $815.21k

Ms. Molly Henderson CPA (Age 52)
MBA, Chief Financial & Bus. Officer
Comp: $671.27k

Mr. Aditya Kohli Ph.D. (Age 35)
Co-Founder

Mr. Anthony J. Guzzo (Age 50)
Chief Accounting Officer

Mr. Joseph Hand J.D.
Chief Admin. Officer

Mr. Lawrence Miller Esq.
J.D., Gen. Counsel & Sec.

Mr. Tom Harris
Chief Devel. Sciences Officer

Dr. Eckhard Leifke M.D.
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PHAT Stock - Frequently Asked Questions

Should I buy or sell Phathom Pharmaceuticals stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHAT shares.
View PHAT analyst ratings or view top-rated stocks.
What is Phathom Pharmaceuticals' stock price forecast for 2023?: 7 analysts have issued twelve-month price objectives for Phathom Pharmaceuticals' stock. Their PHAT share price forecasts range from $16.00 to $30.00. On average, they predict the company's stock price to reach $23.33 in the next year. This suggests a possible upside of 127.0% from the stock's current price.
View analysts price targets for PHAT or view top-rated stocks among Wall Street analysts.
How have PHAT shares performed in 2023?: Phathom Pharmaceuticals' stock was trading at $11.22 at the beginning of 2023. Since then, PHAT shares have decreased by 8.4% and is now trading at $10.28.
View the best growth stocks for 2023 here.
When is Phathom Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PHAT earnings forecast.
How were Phathom Pharmaceuticals' earnings last quarter?: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its earnings results on Thursday, August, 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.11.
What ETFs hold Phathom Pharmaceuticals' stock?: ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Phathom Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).
When did Phathom Pharmaceuticals IPO?: (PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.
What is Phathom Pharmaceuticals' stock symbol?: Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT."
How do I buy shares of Phathom Pharmaceuticals?: Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Phathom Pharmaceuticals' stock price today?: One share of PHAT stock can currently be purchased for approximately $10.28.
How much money does Phathom Pharmaceuticals make?: Phathom Pharmaceuticals (NASDAQ:PHAT) has a market capitalization of $583.90 million. The company earns $-197,720,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis.
How many employees does Phathom Pharmaceuticals have?: The company employs 112 workers across the globe.
How can I contact Phathom Pharmaceuticals?: Phathom Pharmaceuticals' mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The official website for the company is www.phathompharma.com. The company can be reached via phone at 877-742-8466 or via email at ir@phathompharma.com.

This page (NASDAQ:PHAT) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial